Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Ash 2021 – the sun sets on Kymriah, but Novartis has a plan
Novartis unveils the first clinical backing for a two-day manufacturing technique that it hopes will recharge its Car-T efforts.
Ash 2021 – Sangamo and Sanofi enter the sickle cell gene editing fray
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
Ash 2021 – Bluebird looks to revive Lentiglobin
Data in sickle cell disease look encouraging, but a filing is a way away.
Go or go go? J&J’s cell therapy heads to the FDA
November approval decisions loom for cilta-cel and Voxzogo, while molnupiravir heads for an advisory panel.
Global Blood takes on gene therapy
Proof-of-concept data at Ash should give clues about whether GBT021601 could be an oral functional cure for sickle cell disease.
Springworks seeks cancer win as a prelude to something bigger
The young biotech is well placed to deliver its first pivotal win, but investor focus might lie elsewhere.
Roxadustat shows the latest regulatory fault line split
Fibrogen’s controversial anaemia pill becomes the latest example of markedly different regulatory stances taken in Europe and the US.
